



256  
4#

**TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING  
REJECTION OVER A PENDING SECOND APPLICATION**

Docket Number (Optional)

CELLTH 3.0-003 CONT CONT XVI

In re Application of: Raymond P. Warrell, Jr., Pier Paolo Pandolfi, and Janice L. Gabrilove

Application No.: 10/759,290

Filed: January 16, 2004

For: PROCESS FOR PRODUCING ARSENIC TRIOXIDE FORMULATIONS AND METHODS FOR  
TREATING CANCER USING ARSENIC TRIOXIDE OR MELARSOPROL

The owner\*, Memorial Sloan-Kettering Cancer Center, of 100

percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on the following pending related applications:

10/758,800 filed on January 16, 2004  
10/758,993 filed on January 16, 2004  
10/758,994 filed on January 16, 2004  
10/758,996 filed on January 16, 2004  
10/759,291 filed on January 16, 2004  
10/759,293 filed on January 16, 2004  
10/759,308 filed on January 16, 2004  
10/759,313 filed on January 16, 2004

10/759,314 filed on January 16, 2004  
10/759,439 filed on January 16, 2004  
10/759,616 filed on January 16, 2004  
10/759,657 filed on January 16, 2004  
10/758,995 filed on January 16, 2004  
10/759,716 filed on January 16, 2004  
10/759,726 filed on January 16, 2004  
10/759,882 filed on January 16, 2004

of any patent on the above-listed pending related applications. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the above-listed pending related applications are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the above-listed pending applications, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Check either box 1 or 2 below, if appropriate.

1. ☐ For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney or agent of record.

Shawn P. Foley August 31, 2004  
Signature Date

Shawn P. Foley - 33,071  
Typed or printed name

- ☒ The Commissioner is hereby authorized to charge the disclaimer fee under 37 CFR 1.20(d) to  
Deposit Account No. 12-1095

LD-543\512402\_1.DOC